Literature DB >> 1732120

Factors influencing the eradication of Helicobacter pylori with triple therapy.

D Y Graham1, G M Lew, H M Malaty, D G Evans, D J Evans, P D Klein, L C Alpert, R M Genta.   

Abstract

Helicobacter pylori infection has been associated with gastritis, duodenal ulcer, gastric ulcer, and the epidemic form of gastric carcinoma. Eradication of H. pylori infection has proven to be difficult. Recently, combinations of antimicrobial drugs have been shown to eradicate greater than 50% of infections; however, the results have proven variable, and the factors influencing effectiveness of therapy are unclear. In the present study, the effectiveness of a triple therapy for eradication of H. pylori infection was evaluated. Triple therapy consisted of 2 g tetracycline, 750 mg metronidazole, and five or eight tablets of bismuth subsalicylate daily in 93 patients (70 with duodenal ulcer, 17 with gastric ulcer, and 6 with simple H. pylori gastritis). Combinations of a sensitive urea breath test, serology, culture, and histology were used to confirm the presence of infection, eradication, or relapse. Eradication was defined as inability to show H. pylori greater than or equal to 1 month after ending therapy. The overall eradication rate was 87%. The factors evaluated for their effect on predicting eradication included age, gender, type of disease, duration of therapy, amount of bismuth subsalicylate [five or eight Pepto-Bismol tablets daily (Procter & Gamble, Cincinnati, OH)], and compliance with the prescribed medications. Stepwise regression showed that compliance was the most important factor predicting success; the success rate was 96% for patients who took greater than 60% of the prescribed medications and 69% for patients who took less. For those taking greater than 60% of the prescribed therapy, the eradication rates were similar (a) for patients receiving therapy for 14 days or when tetracycline and bismuth subsalicylate were taken for an additional 14 days; (b) for patients with duodenal ulcer, gastric ulcer, and simple H. pylori gastritis; and (c) whether five or eight bismuth subsalicylate tablets were taken. It is concluded that triple therapy is effective for eradication of H. pylori and that future studies need to take compliance into account for comparisons between regimens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732120     DOI: 10.1016/0016-5085(92)90095-g

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  98 in total

Review 1.  Presentation and management of Helicobacter pylori infection in childhood.

Authors:  U Blecker; N K Mittal; D I Mehta
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

2.  Patient education for H pylori: who benefits?

Authors:  Katherine Yang; B Joseph Guglielmo
Journal:  West J Med       Date:  2002-03

3.  Helicobacter Pylori.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

Review 4.  Helicobacter pylori infection and eradication in paediatric patients.

Authors:  H M Malaty
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

5.  Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori.

Authors:  Margareta Svensson; Lennart E Nilsson; Magnus Ström; Maud Nilsson; Mikael Sörberg
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 6.  Helicobacter pylori eradication in patients with non-ulcer dyspepsia.

Authors:  H H Xia; N J Talley
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

7.  Improving compliance with helicobacter pylori eradication therapy: when and how?

Authors:  John P Anthony O'Connor; Ikue Taneike; Colm O'Morain
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

8.  In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection.

Authors:  Osamu Kamoda; Kinsei Anzai; Jun-ichi Mizoguchi; Masatoshi Shiojiri; Toshiharu Yanagi; Takeshi Nishino; Shigeru Kamiya
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

9.  Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone.

Authors:  G Bianchi Porro; F Parente; M Lazzaroni
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

10.  High Helicobacter pylori numbers are associated with low eradication rate after triple therapy.

Authors:  M Moshkowitz; F M Konikoff; Y Peled; M Santo; A Hallak; Y Bujanover; E Tiomny; T Gilat
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.